Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Brian I. Rini(Vanderbilt University Medical Center), Thomas Powles(Queen Mary University of London), Bohuslav Melichar(Palacký University Olomouc), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Julia F. Markensohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth R. Plimack(Fox Chase Cancer Center), Rustem Gafanov(Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology), Ihor Vynnychenko(Sumy State University), V.P. Stus, Joseph E. Burgents(Merck & Co., Inc., Rahway, NJ, USA (United States)), Frédéric Pouliot(Université Laval), Dmitry Nosov(Central Clinical Hospital), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sterling Wu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jens Bedke, Satoshi Tamada(Berurando General Hospital), Amir Vajdi(Dana-Farber Cancer Institute), Yiwei Zhang(Anhui University of Science and Technology), Delphine Borchiellini(Université Côte d'Azur), Tom Waddell(The Christie NHS Foundation Trust), Ray McDermott(St. Vincent's University Hospital)
Cited by 44
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k